Note 1 — Summary of Operations and Significant Accounting
Policies
Nature of Business and Operations
Albany Molecular Research, Inc. (the
“Company”) is a leading global contract research and manufacturing organization providing customers fully integrated
drug discovery, development, and manufacturing services. We supply a broad range of services and technologies supporting the discovery
and development of pharmaceutical products, the manufacturing of Active Pharmaceutical Ingredients (“API”) and the
manufacturing of drug product for new and generic drugs, as well as research, development and manufacturing for the agrochemical
and other industries. With locations in the United States, Europe, and Asia, we maintain geographic proximity to our customers
and flexible cost models.
Basis of Presentation
The accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In accordance with Rule 10-01, the unaudited
condensed consolidated financial statements do not include all of the information and footnotes required by U.S. generally accepted
accounting principles for complete consolidated financial statements. The year-end condensed consolidated balance sheet data was
derived from audited financial statements but does not include all disclosures required by U.S. generally accepted accounting
principles. In the opinion of management, all adjustments (consisting of normal recurring accruals and adjustments) considered
necessary for a fair statement of the results for the interim period have been included. Operating results for the three months
ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31,
2016. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated
financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.
The accompanying unaudited condensed consolidated
financial statements include the accounts of the Company and its wholly-owned subsidiaries as of March 31, 2016. All intercompany
balances and transactions have been eliminated during consolidation. Assets and liabilities of non-U.S. operations are translated
at period-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the period.
Gains or losses resulting from translating non-U.S. currency financial statements are recorded in the unaudited condensed consolidated
statements of comprehensive income and in accumulated other comprehensive loss in the accompanying unaudited condensed consolidated
balance sheets. When necessary, prior years’ unaudited condensed consolidated financial statements have been reclassified
to conform to the current year presentation.
Use of Management Estimates
The preparation of financial statements
in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, at the date of the financial
statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates included
in the accompanying consolidated financial statements include assumptions regarding the valuation of inventory, intangible assets,
and long-lived assets, assumptions associated with our accounting for business combinations and goodwill impairment assessment,
and the amount and realizability of deferred tax assets. Other significant estimates include assumptions utilized in determining
actuarial obligations in conjunction with the Company’s pension and postretirement health plans, assumptions utilized in
determining stock-based compensation, as well as those utilized in determining the value of both the notes hedges and the notes
conversion derivative and the assumptions related to the collectability of receivables. Actual results can vary from these estimates.
Contract Revenue Recognition
The Company’s contract revenue consists
primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. Reimbursed
expenses consist of chemicals and other project specific costs. The Company also seeks to include provisions in certain contracts
that contain a combination of up-front licensing fees, milestone and royalty payments should the Company’s proprietary technology
and expertise lead to the discovery of new products that become commercial. Generally, the Company’s contracts may be terminated
by the customer upon 30 days’ to two years’ prior notice, depending on the terms and/or size of the contract.
The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a
single unit of accounting in accordance with the Financial Accounting Standards Board’s (the “FASB”) Accounting
Standards Codification (“ASC”) 605-25, “Revenue Arrangements with Multiple Deliverables,” and Staff Accounting
Bulletin (“SAB”) 104, “Revenue Recognition”. Allocation of revenue to individual elements that qualify
for separate accounting is based on the separate selling prices determined for each component, and total contract consideration
is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company
will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant
market factors.
The Company generates contract revenue
under the following types of contracts:
Fixed-Fee
. Under a fixed-fee contract,
the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion
of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed and when delivery
is made or title and risk of loss otherwise transfers to the customer, and collection is reasonably assured. In certain instances,
the Company’s customers request that the Company retain materials produced upon completion of the project due to the fact
that the customer does not have a qualified facility to store those materials or for other reasons. In these instances, the revenue
recognition process is considered complete when project documents have been delivered to the customer, as required under the arrangement,
or other customer-specific contractual conditions have been satisfied.
Full-time Equivalent (“FTE”)
. An
FTE agreement establishes the number of Company employees contracted for a project or a series of projects, the duration of the
contract period, the price per FTE, plus an allowance for chemicals and other project specific costs, which may or may not be
incorporated in the FTE rate. FTE contracts can run in one month increments, but typically have terms of six months or longer.
FTE contracts typically provide for annual adjustments in billing rates for the scientists assigned to the contract.
These contracts involve the Company’s
scientists providing services on a “best efforts” basis on a project that may involve a research component with a
timeframe or outcome that has some level of unpredictability. There are no fixed deliverables that must be met for payment as
part of these services. As such, the Company recognizes revenue under FTE contracts on a monthly basis as services are performed
according to the terms of the contract.
Time and Materials
. Under a time
and materials contract, the Company charges customers an hourly rate plus reimbursement for chemicals and other project specific
costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied
by the customer’s billing rate plus other project specific costs incurred.
Recurring Royalty and Milestone Revenues
Recurring Royalty Revenue
.
Recurring royalties have historically related to royalties under a license agreement with Sanofi based on the worldwide net sales
of fexofenadine HCl, marketed as Allegra in the Americas and Telfast elsewhere, as well as on sales of Sanofi’s authorized
or licensed generics and sales by certain authorized sub-licensees. These royalty payments ceased in May 2015 due to the expiration
of patents under the license agreement. The Company currently receives royalties on net sales of generic products sold by Allergan,
plc (“Allergan”) in conjunction with a Development and Supply Agreement. The Company records royalty revenue in the
period in which the net sales of this product occur. Royalty payments from Allergan are due within 60 days after each calendar
quarter and are determined based on sales of the qualifying products in that quarter. The Company also receives royalties on certain
other products.
Up-Front License Fees and Milestone
Revenue
.
The Company recognizes revenue from up-front non-refundable licensing fees on a straight-line basis over the
period of the underlying project. The Company will recognize revenue arising from a substantive milestone payment upon the successful
achievement of the event, and the resolution of any uncertainties or contingencies regarding potential collection of the related
payment, or if appropriate over the remaining term of the agreement.
In 2014, the Company entered into development
and supply agreements with Genovi Pharmaceuticals Limited which have subsequently been transferred to HBT Labs, Inc. (“HBT”)
to manufacture select generic parenteral drug products for registration and subsequent commercialization in the U.S., Europe,
and select emerging markets.
Under the terms of these HBT Agreements,
the Company may receive milestone payments for each drug product candidate upon achievement of certain developments milestones
including technology transfer activities, analytical development activities, and manufacture of regulatory submission batches.
Following U.S. Food and Drug Administration approval, the Company will supply generic parenteral drug products to HBT pursuant
to the HBT Agreements and receive payments based on HBT’s sales of such products.
The Company has determined these milestones
payments to be substantive milestones in accordance with ASC 605-28-25, “Revenue Recognition – Milestone Method”
(“ASC 605”). In evaluating these milestones, the Company considered the following:
|
·
|
Each individual
milestone is considered to be commensurate with the enhanced value of the underlying licensed intellectual property or drug
product candidate as they are advanced from the development stage to a commercialized product, and considered them to be reasonable
when evaluated in relation to the total agreement consideration, including other milestones.
|
|
·
|
The milestones are
deemed to relate solely to past performance, as each milestone is payable to the Company only after the achievement of the
related event defined in the agreement, and is not refundable if additional future success events do not occur.
|
For the three months ended March 31, 2016
and 2015, no milestone revenue was recognized by the Company.
Proprietary Drug Development Arrangements
The Company has discovered and conducted
the early development of several new drug candidates, with a view to out-licensing these candidates to partners for further development
in return for a potential combination of up-front license fees, milestone payments and recurring royalty payments if compounds
resulting from our intellectual property are successfully developed into new drugs and reach the market. The Company does not
anticipate milestone or recurring royalty payments under its current license arrangements to have a significant impact on the
Company’s consolidated operating results, financial position, or cash flows.
Cash, Cash Equivalents and Restricted
Cash
Cash equivalents consist of money market
accounts and overnight deposits. For purposes of the consolidated statements of cash flows, the Company considers all highly liquid
investments with a maturity of three months or less when purchased to be cash equivalents.
Restricted cash balances at March 31,
2016 and December 31, 2015, are required as collateral for the letters of credit associated with our debt agreements.
Long-Lived Assets
The Company assesses the impairment of
a long-lived asset group whenever events or changes in circumstances indicate that its carrying value may not be recoverable.
Factors the Company considers important that could trigger an impairment review include, among others, the following:
|
·
|
a
significant change in the extent or manner in which a long-lived asset group is being
used;
|
|
·
|
a
significant change in the business climate that could affect the value of a long-lived
asset group; or
|
|
·
|
a
significant decrease in the market value of assets.
|
If the Company determines that the carrying
value of long-lived assets may not be recoverable, based upon the existence of one or more of the above indicators of impairment,
the Company compares the carrying value of the asset group to the undiscounted cash flows expected to be generated by the asset
group. If the carrying value exceeds the undiscounted cash flows, an impairment charge is indicated. An impairment charge is recognized
to the extent that the carrying amount of the asset group exceeds its fair value and will reduce only the carrying amounts of
the long-lived assets.
Derivative
Instruments and Hedging Activities
The Company accounts for derivatives in
accordance with FASB ASC Topic 815, “Derivatives and Hedging”, which establishes accounting and reporting standards
requiring that derivative instruments be recorded on the balance sheet as either an asset or a liability measured at fair value.
Additionally, changes in a derivative’s fair value shall be recognized currently in earnings unless specific hedge accounting
criteria are met. If the specific hedge accounting criteria is met, then changes in fair value are recorded in accumulative other
comprehensive loss, net.
Recently Issued Accounting Pronouncements
In March 2016, the Financial Accounting
Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, “Compensation –
Stock Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting”, which changes the accounting
for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities,
and classification in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15,
2016 and for interim periods therein with early adoption permitted. The Company is currently evaluating the impact this ASU will
have on its consolidated financial statements.
In February 2016, the FASB issued ASU
No. 2016-02, “Leases (Topic 842)”. The new standard establishes a right-of-use (“ROU”) model that
requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months.
Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in
the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim
periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating
leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements,
with certain practical expedients available. The Company is currently evaluating the impact this ASU will have on its consolidated
financial statements.
In July 2015, the FASB issued ASU No.
2015-11, “Simplifying the Measurement of Inventory.” This ASU simplifies the measurement of inventory by requiring
certain inventory to be measured at the lower of cost or net realizable value. The amendments in this ASU are effective for fiscal
years beginning after December 15, 2016 and for interim periods therein. The Company is currently evaluating the impact this ASU
will have on its consolidated financial statements.
In August 2014, the FASB issued ASU, No. 2014-15,
“Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s
Ability to Continue as a Going Concern”, which defines management’s responsibility to assess an entity’s ability
to continue as a going concern, and to provide related footnote disclosures if there is substantial doubt about its ability to
continue as a going concern. The pronouncement is effective for annual reporting periods ending after December 15, 2016,
with early adoption permitted. The Company does not expect this ASU to have a material impact on its consolidated financial statements.
In June 2014, the FASB issued ASU No.
2014-12, “Compensation - Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide
That a Performance Target Could Be Achieved after the Requisite Service Period.” This ASU requires that a performance target
that affects vesting and that could be achieved after the requisite service period, be treated as a performance condition. The
performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized
in the period in which it becomes probable that the performance target will be achieved and should represent the compensation
cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes
probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should
be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during
and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to
reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and
still be eligible to vest in the award if the performance target is achieved. This ASU is effective for annual periods and interim
periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The adoption
of this ASU did not have a material impact on the Company’s consolidated financial statements.
In May 2014, the FASB issued ASU No. 2014-09,
“Revenue from Contracts with Customers: (Topic 606).” This ASU affects any entity that either enters into contracts
with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts
are within the scope of other standards (e.g., insurance contracts or lease contracts). This ASU will supersede the revenue recognition
requirements in ASC Topic 605, “Revenue Recognition,” and most industry-specific guidance. In addition, the existing
requirements for the recognition of a gain or loss on the transfer of nonfinancial assets that are not in a contract with a customer
(e.g., assets within the scope of ASC Topic 360, “Property, Plant, and Equipment,” and intangible assets within the
scope of ASC Topic 350, “Intangibles-Goodwill and Other”) are amended to be consistent with the guidance on recognition
and measurement (including the constraint on revenue) in this ASU. The core principle of the guidance is that an entity should
recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration
to which the entity expects to be entitled in exchange for those goods or services. In July 2015, the FASB deferred the effective
date of ASU 2014-09. This ASU is now effective for calendar years beginning after December 15, 2017. Early adoption
is not permitted. The Company is currently evaluating the impact this ASU will have on its consolidated financial statements.
Note 2 — Earnings Per Share
The shares used in the computation of
the Company’s basic and diluted earnings per share are as follows:
|
|
Three Months Ended March
31,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
|
|
|
|
|
Weighted average common
shares outstanding – basic and diluted
|
|
|
34,718
|
|
|
|
32,827
|
|
The Company has excluded certain outstanding
stock options, non-vested restricted stock and warrants from the calculation of diluted earnings per share for the three months
ended March 31, 2016 and 2015 because the net loss causes these amounts to be anti-dilutive. The weighted average number of anti-dilutive
common equivalents outstanding (before the effects of the treasury stock method) was 11,703 and 12,294 for the three months ended
March 31, 2016 and 2015, respectively. These amounts are not included in the calculation of weighted average common shares outstanding.
Note 3 – Business Acquisitions
Glasgow
On January
8, 2015, the Company completed the purchase of all of the outstanding equity interests of Aptuit’s Glasgow, U.K. business, now
Albany Molecular Research (Glasgow) Limited (“Glasgow”), for total consideration of $23,805 (net of cash acquired
of $146). The Glasgow facility extends the Company’s capabilities to sterile injectable drug product pre-formulation, formulation
and clinical stage manufacturing. Glasgow has been assigned to the Drug Product Manufacturing (“DPM”) segment.
SSCI
On February
13, 2015, the Company completed the purchase of assets and assumed certain liabilities of Aptuit’s Solid State Chemical Information
business, now AMRI SSCI, LLC (“SSCI”), for total consideration of $35,850. SSCI brings extensive material science knowledge
and technology and expands the Company’s capabilities in analytical testing to include peptides, proteins and oligonucleotides.
SSCI has been assigned to the Discovery and Development Services (“DDS”) segment.
Gadea Grupo
On July 16, 2015, the Company completed
the purchase of Gadea Grupo Farmaceutico, S.L. (“Gadea”), a contract manufacturer of complex active pharmaceutical
ingredients (“APIs”) and finished drug product. Gadea operates within the Company’s API and DPM segments. The
aggregate net purchase price was $127,572 (net of cash acquired of $10,961), which included the issuance of 2,200 shares of common
stock, valued at $40,568, with the balance comprised of $96,961 in cash, plus a working capital adjustment of $1,004. The purchase
price has been allocated based on an estimate of the fair value of assets and liabilities acquired as of the acquisition date.
The following table summarizes the allocation of the aggregate purchase price to the estimated fair value of the net assets acquired:
|
|
July 16,
2015
|
|
Assets Acquired
|
|
|
|
|
Accounts receivable
|
|
$
|
23,756
|
|
Prepaid expenses and other current assets
|
|
|
3,334
|
|
Inventory
|
|
|
47,400
|
|
Property and equipment
|
|
|
29,420
|
|
Deferred tax assets
|
|
|
1,115
|
|
Intangible assets
|
|
|
58,200
|
|
Goodwill
|
|
|
51,563
|
|
Other long term-assets
|
|
|
2,053
|
|
Total assets acquired
|
|
$
|
216,841
|
|
|
|
|
|
|
Liabilities Assumed
|
|
|
|
|
Accounts payable and accrued expenses
|
|
$
|
18,103
|
|
Debt
|
|
|
44,523
|
|
Income taxes payable
|
|
|
5,920
|
|
Deferred income taxes
|
|
|
19,179
|
|
Other long-term liabilities
|
|
|
1,544
|
|
Total liabilities assumed
|
|
|
89,269
|
|
Net assets acquired
|
|
$
|
127,572
|
|
The purchase
price was adjusted in the first quarter of 2016 by $676 due to the finalization of the net working capital adjustment. The purchase
price allocation was adjusted in the first quarter of 2016, primarily due to the recognition of an environmental remediation liability
of $1,542, and a corresponding indemnification receivable from the seller of $771. These adjustments resulted in a net increase
of goodwill of approximately $1,400. The Company will finalize the purchase price allocation in the second quarter of 2016. Remaining
allocation adjustments are not expected to be significant.
The Company has attributed the goodwill of $51,563 to an expanded global
footprint and additional market opportunities that the Gadea business offers. The goodwill has been allocated between business
segments, with API of $31,084 and DPM of $20,479, and is not deductible for tax purposes. Intangible assets acquired consisted
of customer relationships of $24,000 (with an estimated life of 13 years), a tradename of $4,100 (with an indefinite estimated
life), intellectual property of $11,900 (with an estimated life of 15 years), in-process research and development of $18,000 (with
an indefinite estimated life), and $200 of order backlog.
Whitehouse
Laboratories
On December
15, 2015, the Company acquired all the outstanding equity interests of Whitehouse Analytical Laboratories, LLC (“Whitehouse”),
a leading provider of testing services that includes chemical and material analysis, method development and validation and quality
control verification services to the pharmaceutical, medical device and personal care industries. Whitehouse offers a comprehensive
array of testing solutions for life sciences from materials and excipients, container qualification and container closure integrity
testing, routine analytical chemistry, drug delivery systems and device qualification programs, packaging, distribution, and stability
and storage programs. The aggregate net purchase price was $55,986 (net of cash acquired of $377), which included the issuance
of 137 shares of common stock, valued at $1,800, with the balance comprised of $53,924 in cash, plus a working capital adjustment
of $262.
The following table summarizes the final allocation of the aggregate purchase price to the estimated fair value of the
net assets acquired:
|
|
December
15, 2015
|
|
Assets Acquired
|
|
|
|
|
Accounts receivable
|
|
$
|
2,084
|
|
Prepaid expenses and other current assets
|
|
|
34
|
|
Property and equipment
|
|
|
982
|
|
Intangible assets
|
|
|
26,200
|
|
Goodwill
|
|
|
26,732
|
|
Total assets acquired
|
|
$
|
56,032
|
|
|
|
|
|
|
Liabilities Assumed
|
|
|
|
|
Accounts payable and accrued expenses
|
|
$
|
46
|
|
Total liabilities assumed
|
|
|
46
|
|
Net assets acquired
|
|
$
|
55,986
|
|
The purchase price was increased in the
first quarter of 2016 by $262 due to the finalization of the net working capital adjustment. The purchase price was reduced in
the first quarter of 2016 to recognize the discount associated with the 137 shares of restricted shares issued in conjunction with
the Whitehouse acquisition in the amount of $200. These adjustments resulted in a net increase of goodwill of $62.
The Company has attributed the goodwill
of $26,732 to additional market opportunities that the Whitehouse business offers within the DDS segment. The goodwill is deductible
for tax purposes. Intangible assets acquired consisted of customer lists of $25,600, with an estimated life of 13 years, and a
tradename of $600, with an estimated life of 8 years.
The following table shows the unaudited
pro forma statement of operations for the three months ended March 31, 2015, as if the Gadea, Whitehouse, Glasgow and SSCI acquisitions
had occurred on January 1, 2014. This pro forma information does not purport to represent what the Company’s actual results
would have been if the acquisitions had occurred as of the date indicated or what such results would be for any future periods.
|
|
(Unaudited)
|
|
Total revenues
|
|
$
|
104,640
|
|
Net Loss
|
|
|
(156
|
)
|
Pro forma weighted average shares
|
|
|
35,164
|
|
Pro forma loss per share:
|
|
|
|
|
Basic
|
|
$
|
(0.00
|
)
|
Diluted
|
|
$
|
(0.00
|
)
|
The following table shows the pro forma
adjustments made to the weighted average shares outstanding for the three months ended March 31, 2015:
Weighted average common shares outstanding – basic
|
|
|
32,827
|
|
Pro forma impact of acquisition consideration
|
|
|
2,337
|
|
Pro forma weighted average shares
|
|
|
35,164
|
|
For the three-month period ended March
31, 2015, pre-tax net income was adjusted by reducing expenses by $985 for acquisition related costs and increasing expenses by
$1,307 for purchase accounting related depreciation and amortization.
The Company partially funded the acquisition
of Whitehouse utilizing the proceeds from a $30,000 revolving line of credit. For purposes of presenting the pro forma statement
of operations for the three months ended March 31, 2015, the Company has assumed that it borrowed on the revolving line of credit
on January 1, 2014 for an amount sufficient to fund the cash consideration to acquire Whitehouse as of that date. The pro forma
statement of operations for the three months ended March 31, 2015 reflects the recognition of interest expense that would have
been incurred on the revolving line of credit had it been entered into on January 1, 2014. The Company has recorded $425 of pro
forma interest expense on the revolving line of credit for the purposes of presenting the pro forma statement of operations for
the three months ended March 31, 2015.
The Company partially funded the acquisition
of Gadea utilizing the proceeds from a $200,000 term loan that was provided for in conjunction with a $230,000 senior secured
credit agreement (the “Credit Agreement”) with Barclays Bank PLC that was completed in July 2015 (see note 5). The
Company did not have sufficient cash on hand to complete the acquisition as of January 1, 2014. For the purposes of presenting
the pro forma statement of operations for the three months ended March 31, 2015, the Company has assumed that it entered into
the Credit Agreement on January 1, 2014 for an amount sufficient to fund the preliminary cash consideration to acquire Gadea as
of that date. The pro forma statement of operations for the three months ended March 31, 2015 reflect the recognition of interest
expense that would have been incurred on the Credit Agreement had it been entered into on January 1, 2014. The Company has recorded
$2,100 of pro forma interest expense on the Credit Agreement for the purposes of presenting the pro forma statement of operations
for the three months ended March 31, 2015.
Note 4 — Inventory
Inventory consisted of the following as of March 31, 2016 and
December 31, 2015:
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
Raw materials
|
|
$
|
37,103
|
|
|
$
|
37,483
|
|
Work in process
|
|
|
28,402
|
|
|
|
29,341
|
|
Finished goods
|
|
|
28,575
|
|
|
|
22,407
|
|
Total inventories, at cost
|
|
$
|
94,080
|
|
|
$
|
89,231
|
|
Note 5 –Debt
The following table summarizes long-term debt:
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
Convertible senior notes, net of unamortized debt discount
|
|
$
|
130,561
|
|
|
$
|
128,917
|
|
Term loan, net of unamortized discount
|
|
|
197,514
|
|
|
|
198,343
|
|
Revolving credit facility
|
|
|
30,000
|
|
|
|
30,000
|
|
Industrial development authority bond
|
|
|
2,080
|
|
|
|
2,080
|
|
Various borrowings with institutions, Gadea loans
|
|
|
36,196
|
|
|
|
39,655
|
|
Capital leases – equipment & other
|
|
|
70
|
|
|
|
111
|
|
|
|
|
396,421
|
|
|
|
399,106
|
|
Less deferred financing fees
|
|
|
(8,853
|
)
|
|
|
(9,823
|
)
|
Less current portion
|
|
|
(13,843
|
)
|
|
|
(15,591
|
)
|
Total long-term debt
|
|
$
|
373,725
|
|
|
$
|
373,692
|
|
The aggregate maturities of long-term debt, exclusive of unamortized
debt discount of $20,925 at March 31, 2016, are as follows:
2016 (remaining)
|
|
$
|
9,901
|
|
2017
|
|
|
12,299
|
|
2018
|
|
|
355,011
|
|
2019
|
|
|
6,407
|
|
2020
|
|
|
32,407
|
|
Thereafter
|
|
|
1,321
|
|
Total
|
|
$
|
417,346
|
|
Term Loan
The components of the term loan under the
Company’s Second Amended and Restated Credit Agreement with Barclays Bank PLC, dated as of August 19, 2015 (the “Second
Restated Credit Agreement”) were as follows:
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
Principal amount – term loan
|
|
$
|
199,000
|
|
|
$
|
200,000
|
|
Unamortized debt discount
|
|
|
(1,486
|
)
|
|
|
(1,657
|
)
|
Net carrying amount of term loan
|
|
$
|
197,514
|
|
|
$
|
198,343
|
|
Convertible Senior Notes
On December 4, 2013, the Company completed
a private offering of $150,000 aggregate principal amount of 2.25% Cash Convertible Senior Notes (the “Notes”), between
the Company and Wilmington Trust, National Association, as Trustee. The Notes mature on November 15, 2018, unless earlier
repurchased or converted into cash in accordance with their terms prior to such date and interest is paid in arrears semiannually
on each May 15 and November 15 at an annual rate of 2.25% beginning on May 15, 2014. The Notes were offered and sold only to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).
The Notes are not convertible into the
Company’s common stock or any other securities under any circumstances. Holders may convert their Notes solely into cash at their
option at any time prior to the close of business on the business day immediately preceding May 15, 2018 only under the following
circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2013 (and only during
such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or
not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar
quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business
day period after any five consecutive trading day period in which the trading price per thousand dollars principal amount of Notes
for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s
common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events. On or
after May 15, 2018 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders
may convert their Notes solely into cash at any time, regardless of the foregoing circumstances. Upon conversion, in lieu of receiving
shares of the Company’s common stock, a holder will receive, per thousand dollars principal amount of Notes, an amount in cash
equal to the settlement amount, determined in the manner set forth in the indenture. The initial conversion rate is 63.9844 shares
of the Company’s common stock per thousand dollars principal amount of Notes (equivalent to an initial conversion price of approximately
$15.63 per share of common stock). The conversion rate is subject to adjustment in some events as described in the Indenture but
will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to
the maturity date, the Company has agreed to pay a cash make-whole premium by increasing the conversion rate for a holder who
elects to convert its Notes in connection with such a corporate event in certain circumstances as described in the indenture.
The Company may not redeem the Notes prior
to the maturity date, and no sinking fund is provided for the Notes.
The cash conversion feature of the Notes
(“Notes Conversion Derivative”) requires bifurcation from the Notes in accordance with ASC Topic 815,
Derivatives
and Hedging
, and is accounted for as a derivative liability. The fair value of the Notes Conversion Derivative at the time
of issuance of the Notes was $33,600 and was recorded as original debt discount for purposes of accounting for the debt component
of the Notes. This discount is amortized as interest expense using the effective interest method over the term of the Notes. For
the three months ended March 31, 2016, the Company recorded $1,644 of amortization of the debt discount as interest expense based
upon an effective rate of 7.69%.
The components of the Notes were as follows:
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
Principal amount
|
|
$
|
150,000
|
|
|
$
|
150,000
|
|
Unamortized debt discount
|
|
|
(19,439
|
)
|
|
|
(21,083
|
)
|
Net carrying amount of Notes
|
|
$
|
130,561
|
|
|
$
|
128,917
|
|
In connection with the pricing of the
Notes, on November 19, 2013, the Company entered into cash convertible note hedge transactions (“Notes Hedges”) relating
to a notional number of shares of the Company’s common stock underlying the Notes to be issued by the Company with two counterparties
(the “Option Counterparties”). The Notes Hedges, which are cash-settled, are intended to reduce the Company’s
exposure to potential cash payments that we are required to make upon conversion of the Notes in excess of the principal amount
of converted notes if our common stock price exceeds the conversion price. The Notes Hedges are accounted for as a derivative
instrument in accordance with ASC Topic 815. The aggregate cost of the note hedge transaction was $33,600.
At the same time, the Company also entered
into separate warrant transactions with each of the Option Counterparties initially relating, in the aggregate, to 9,598 shares
of the Company’s common stock underlying the Note Hedges. The cash convertible Note Hedges are intended to offset cash payments
due upon any conversion of the Notes. However, the warrant transactions could separately have a dilutive effect to the extent
that the market price per share of the Company’s common stock (as measured under the terms of the warrant transactions) exceeds
the applicable strike price of the warrants. The initial strike price of the warrants is $18.9440 per share, which was 60% above
the last reported sale price of the Company’s common stock of $11.84 on November 19, 2013 and proceeds of $23,100 were received
from the Option Counterparties from the sale of the warrants.
Aside from the initial payment of a
$33,600 premium to the Option Counterparties, the Company is not required to make any cash payments to the Option
Counterparties under the Note Hedges and will be entitled to receive from the Option Counterparties an amount of cash,
generally equal to the amount by which the market price per share of common stock exceeds the strike price of the Note Hedges
during the relevant valuation period. The strike price under the Note Hedges is initially equal to the conversion price of
the Notes. Additionally, if the market price per share of the Company’s common stock, as measured under the warrant
transactions, exceeds the strike price of the warrants during the measurement period at the maturity of the warrants, the
Company will be obligated to issue to the Option Counterparties a number of shares of the Company’s common stock in an
amount based on the excess of such market price per share of the Company’s common stock over the strike price of the
warrants. The Company will not receive any proceeds if the warrants are exercised.
Neither the Notes Conversion Derivative
nor the Notes Hedges qualify for hedge accounting, thus any changes in the fair market value of the derivatives is recognized
immediately in the statement of operations. As of March 31, 2016 and December 31, 2015, the changes in fair market value of the
Notes Conversion Derivative and the Notes Hedges were equal, therefore there was no change in fair market value that was recognized
in the statement of operations.
The following table summarizes the fair
value and the presentation in the consolidated balance sheet:
|
|
Location on Balance
Sheet
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
Notes Hedges
|
|
Other assets
|
|
$
|
42,199
|
|
|
$
|
76,393
|
|
Notes Conversion Derivative
|
|
Other liabilities
|
|
$
|
(42,199
|
)
|
|
$
|
(76,393
|
)
|
Note 6 — Impairment, Restructuring and other charges
In April 2015, the Company announced a
restructuring plan with respect to certain operations in the U.K. within its API business segment. In connection with the restructuring
plan, the Company ceased all operations at its Holywell, U.K. facility in the fourth quarter of 2015. The Company recorded $996
in charges for reduction in force and termination benefits and other restructuring-related charges related to the U.K. facility
during the three months ended March 31, 2016. In conjunction with the Company’s actions to cease operations at its Holywell,
U.K. facility, the Company also recorded property and equipment impairment charges of $0 and $2,550 in the API segment in the
three months ended March 31, 2016 and 2015, respectively. These charges are included under the caption “impairment charges”
on the consolidated statement of operations. Also in 2015, the Company made additional resource changes at its Singapore site
(within the DDS segment) to optimize the cost profile of the facility, which resulted in a restructuring charge of $1,427 during
the three months ended March 31, 2016. Equipment that will not be transferred or recovered through sale is subject to accelerated
depreciation over the remaining operating period of the facility.
Restructuring charges for the three months
ended March 31, 2016 and 2015 were $2,600 and $1,487, respectively, consisting primarily of U.K. termination charges and costs
associated with the transfer of continuing products from the Holywell, U.K. facility to our other manufacturing locations, resource
optimization charges at our Singapore facility and lease termination and other charges associated with the previously announced
restructuring at the Company’s Syracuse, NY facility.
The following table displays the restructuring activity and
liability balances for the three-month period ended as of March 31, 2016:
|
|
Balance at
January 1,
2016
|
|
|
Charges/
(reversals)
|
|
|
Amounts
Paid
|
|
|
Foreign
Currency
Translation &
Other
Adjustments
(1)
|
|
|
Balance at
March 31,
2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination benefits and personnel realignment
|
|
$
|
539
|
|
|
$
|
467
|
|
|
|
(549
|
)
|
|
|
4
|
|
|
$
|
461
|
|
Lease termination and relocation charges
|
|
|
2,153
|
|
|
|
57
|
|
|
|
(185
|
)
|
|
|
53
|
|
|
|
2,078
|
|
Other
|
|
|
-
|
|
|
|
2,076
|
|
|
|
(794
|
)
|
|
|
(1,134
|
)
|
|
|
148
|
|
Total
|
|
$
|
2,692
|
|
|
$
|
2,600
|
|
|
|
(1,528
|
)
|
|
|
(1,077
|
)
|
|
$
|
2,687
|
|
|
(1)
|
Included in restructuring
charges are non-cash accelerated depreciation charges of $1,145 related to our Singapore
facility.
|
Termination benefits and personnel realignment
costs related to severance packages, outplacement services, and career counseling for employees affected by the restructuring.
Lease termination charges related to estimated costs associated with exiting a facility, net of estimated sublease income.
Restructuring charges are
included under the caption “Restructuring and other charges” in the consolidated statements of operations for the
three months ended March 31, 2016 and 2015 and the restructuring liabilities are included in “Accounts payable and
accrued expenses” and “other long-term liabilities” on the consolidated balance sheets at March 31, 2016
and December 31, 2015.
Anticipated cash outflow related to the
restructuring reserves as of March 31, 2016 for the remainder of 2016 is approximately $2,687.
The Company is currently marketing its
Syracuse, NY facility for sale, within its DDS operating segment. The facility is classified as for held for sale with the long-lived
assets associated with the Syracuse, NY facility segregated to a separate line item on the consolidated balance sheets until they
are sold and depreciation expense on the location has ceased. The carrying value of the facility is $516 at March 31, 2016. The
Company has entered into an agreement to sell the facility and expects to complete the transaction in the second quarter.
Note 7 — Goodwill and Intangible Assets
The changes in the carrying amount of
goodwill for the three months ended March 31, 2016 were as follows:
|
|
DDS
|
|
|
API
|
|
|
DPM
|
|
|
Total
|
|
Balance as of December 31, 2015
|
|
$
|
45,987
|
|
|
$
|
46,182
|
|
|
$
|
77,302
|
|
|
$
|
169,471
|
|
Measurement period adjustments
|
|
|
62
|
|
|
|
1,416
|
|
|
|
-
|
|
|
|
1,478
|
|
Foreign exchange translation
|
|
|
-
|
|
|
|
1,351
|
|
|
|
582
|
|
|
|
1,933
|
|
Balance as of March 31, 2016
|
|
$
|
46,049
|
|
|
$
|
48,949
|
|
|
$
|
77,884
|
|
|
$
|
172,882
|
|
The components of intangible assets are as follows:
|
|
Cost
|
|
|
Impairment
|
|
|
Accumulated
Amortization
|
|
|
Foreign
exchange
translation
|
|
|
Net
|
|
|
Amortization
Period
|
March 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patents and Licensing Rights
|
|
$
|
20,455
|
|
|
$
|
(2,508
|
)
|
|
$
|
(3,148
|
)
|
|
$
|
(97
|
)
|
|
$
|
14,702
|
|
|
2-16 years
|
Customer Relationships
|
|
|
86,774
|
|
|
|
-
|
|
|
|
(5,853
|
)
|
|
|
886
|
|
|
|
81,807
|
|
|
5-20 years
|
Tradename
|
|
|
4,100
|
|
|
|
-
|
|
|
|
-
|
|
|
|
128
|
|
|
|
4,228
|
|
|
indefinite
|
In-Process Research and Development
|
|
|
18,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
561
|
|
|
|
18,561
|
|
|
indefinite
|
Trademarks
|
|
|
2,200
|
|
|
|
-
|
|
|
|
(824
|
)
|
|
|
-
|
|
|
|
1,376
|
|
|
5 years
|
Order Backlog
|
|
|
200
|
|
|
|
-
|
|
|
|
(151
|
)
|
|
|
3
|
|
|
|
52
|
|
|
n/a
|
Total
|
|
$
|
131,729
|
|
|
$
|
(2,508
|
)
|
|
$
|
(9,976
|
)
|
|
$
|
1,481
|
|
|
$
|
120,726
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost
|
|
|
Impairment
|
|
|
Accumulated
Amortization
|
|
|
Foreign
exchange
translation
|
|
|
Net
|
|
|
Amortization
Period
|
December 31, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patents and Licensing Rights
|
|
$
|
20,352
|
|
|
$
|
(2,508
|
)
|
|
$
|
(3,004
|
)
|
|
$
|
(165
|
)
|
|
$
|
14,675
|
|
|
2-16 years
|
Customer Relationships
|
|
|
86,774
|
|
|
|
-
|
|
|
|
(4,303
|
)
|
|
|
(408
|
)
|
|
|
82,063
|
|
|
5-20 years
|
Tradename
|
|
|
4,100
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(57
|
)
|
|
|
4,043
|
|
|
indefinite
|
In-Process Research and Development
|
|
|
18,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(250
|
)
|
|
|
17,750
|
|
|
indefinite
|
Trademarks
|
|
|
2,200
|
|
|
|
-
|
|
|
|
(727
|
)
|
|
|
-
|
|
|
|
1,473
|
|
|
5 years
|
Order Backlog
|
|
|
200
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
200
|
|
|
n/a
|
Total
|
|
$
|
131,626
|
|
|
$
|
(2,508
|
)
|
|
$
|
(8,034
|
)
|
|
$
|
(880
|
)
|
|
$
|
120,204
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense related to intangible
assets was $1,942 and $750 for the three months ended March 31, 2016 and 2015, respectively. The weighted average amortization
period is 13.2 years.
The following chart represents estimated
future annual amortization expense related to intangible assets:
Year ending December 31,
|
|
|
|
2016 (remaining)
|
|
$
|
5,477
|
|
2017
|
|
|
7,395
|
|
2018
|
|
|
7,390
|
|
2019
|
|
|
7,390
|
|
2020
|
|
|
7,390
|
|
Thereafter
|
|
|
62,843
|
|
Total
|
|
$
|
97,885
|
|
Certain of the Company’s intangible
assets are valued based upon contracts entered into between the Company and development partners and relate to the long-term value
that such contracts are expected to provide to the Company. In the event any one of these contracts were to be modified or
cancelled, the Company may be required to evaluate the recoverability of the intangible assets and the resulting impact on the
valuation of the goodwill recorded with respect to the business unit to which the intangible assets and underlying contracts relate.
In April 2016, we received a purported termination notification from a partner on one of our co-development
agreements. We are in discussions with the partner and assessing all of our options.
Note 8 — Share-Based Compensation
During the three months ended March 31,
2016 and 2015, the Company recognized total share based compensation cost of $2,146 and $1,555, respectively.
The Company grants share-based compensation,
including restricted shares, under its 2008 Stock Option and Incentive Plan, as amended, as well as its 1998 Employee Stock Purchase
Plan, as amended (“ESPP”). The 2008 Stock Option and Incentive Plan and ESPP are together referred to as the “Stock
Option and Incentive Plans”.
Restricted Stock
A summary of unvested restricted stock activity during the
three months ended March 31, 2016 is presented below:
|
|
Number of
Shares
|
|
|
Weighted
Average Grant Date
Fair Value Per
Share
|
|
Outstanding, January 1, 2016
|
|
|
1,020
|
|
|
$
|
13.71
|
|
Granted
|
|
|
381
|
|
|
$
|
15.76
|
|
Vested
|
|
|
(174
|
)
|
|
$
|
13.00
|
|
Forfeited
|
|
|
(23
|
)
|
|
$
|
9.65
|
|
Outstanding, March 31, 2016
|
|
|
1,204
|
|
|
$
|
14.54
|
|
As of March 31, 2016, there was $14,356
of total unrecognized compensation cost related to unvested restricted shares. That cost is expected to be recognized over a weighted-average
period of 2.94 years. Of the 1,204 restricted shares outstanding, the Company currently expects all shares to vest.
Stock Options
The fair value of each stock option award
is estimated at the date of grant using the Black-Scholes valuation model based on the following assumptions:
|
|
For the Three Months Ended
|
|
|
|
March 31,
2016
|
|
|
March 31,
2015
|
|
Expected life in years
|
|
|
5
|
|
|
|
5
|
|
Risk free interest rate
|
|
|
1.25
|
%
|
|
|
1.59
|
%
|
Volatility
|
|
|
42
|
%
|
|
|
42
|
%
|
Dividend yield
|
|
|
—
|
|
|
|
—
|
|
A summary of stock option activity under
the Company’s Stock Option and Incentive Plans during the three-month period ended March 31, 2016 is presented below:
|
|
Number of
Shares
|
|
|
Weighted
Average
Exercise
Price Per Share
|
|
|
Weighted Average
Remaining
Contractual Term
(Years)
|
|
|
Aggregate
Intrinsic
Value
|
|
Outstanding, January 1, 2016
|
|
|
1,439
|
|
|
$
|
8.20
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
295
|
|
|
$
|
15.77
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(31
|
)
|
|
$
|
2.93
|
|
|
|
|
|
|
|
|
|
Expired
|
|
|
—
|
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Outstanding, March 31, 2016
|
|
|
1,703
|
|
|
$
|
9.61
|
|
|
|
5.63
|
|
|
$
|
10,224
|
|
Options exercisable, March 31, 2016
|
|
|
1,080
|
|
|
$
|
7.04
|
|
|
|
5.79
|
|
|
$
|
9,357
|
|
The weighted average fair value of stock
options granted for the three months ended March 31, 2016 and 2015 was $5.98 and $6.51, respectively. As of March 31, 2016, there
was $3,158 of total unrecognized compensation cost related to unvested stock options. That cost is expected to be recognized over
a weighted-average period of 2.94 years. Of the 1,703 stock options outstanding, the Company currently expects all options to
vest.
Employee Stock Purchase Plan
During the three months ended March 31,
2016 and 2015, 37 and 28 shares, respectively, were issued under the Company’s ESPP.
During the three months ended March 31,
2016 and 2015, cash received from stock option exercises and employee stock purchases under the ESPP was $620 and $1,038, respectively.
The excess tax benefit realized for the tax deductions from share based compensation was $0 and $1,153 for the three months ended
March 31, 2016 and 2015, respectively.
Note 9 — Operating Segment Data
The Company has organized its operations
into DDS, API and DPM segments.
The DDS segment includes activities such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.
API includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates and high potency and
controlled substance manufacturing. DPM includes pre-formulation, formulation and process development through commercial scale
production of complex liquid-filled and lyophilized injectable formulations. Corporate activities include sales and marketing
and administrative functions, as well as research and development costs that have not been allocated to the operating segments.
The following table contains earnings data by operating segment,
reconciled to totals included in the unaudited condensed consolidated financial statements:
|
|
Contract
Revenue
|
|
|
Milestone &
Recurring
Royalty
Revenue
|
|
|
Income
(Loss)
from
Operations
|
|
|
Depreciation
and
Amortization
|
|
For the three months ended March 31, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DDS
|
|
$
|
23,203
|
|
|
$
|
—
|
|
|
$
|
4,552
|
|
|
$
|
3,591
|
|
API
|
|
|
54,702
|
|
|
|
2,741
|
|
|
|
12,626
|
|
|
|
3,122
|
|
DPM
|
|
|
24,933
|
|
|
|
—
|
|
|
|
3,270
|
|
|
|
1,811
|
|
Corporate (a)
|
|
|
—
|
|
|
|
—
|
|
|
|
(24,600
|
)
|
|
|
—
|
|
Total
|
|
$
|
102,838
|
|
|
$
|
2,741
|
|
|
$
|
(4,152
|
)
|
|
$
|
8,524
|
|
|
|
Contract
Revenue
|
|
|
Milestone &
Recurring
Royalty
Revenue
|
|
|
Income
(Loss)
from
Operations
|
|
|
Depreciation
and
Amortization
|
|
For the three months ended March 31, 2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DDS (b)
|
|
$
|
17,873
|
|
|
$
|
3,817
|
|
|
$
|
8,383
|
|
|
$
|
1,805
|
|
API
|
|
|
37,848
|
|
|
|
2,868
|
|
|
|
6,797
|
|
|
|
2,421
|
|
DPM (b)
|
|
|
19,410
|
|
|
|
—
|
|
|
|
3,524
|
|
|
|
1,260
|
|
Corporate (a)
|
|
|
—
|
|
|
|
—
|
|
|
|
(17,475
|
)
|
|
|
—
|
|
Total
|
|
$
|
75,131
|
|
|
$
|
6,685
|
|
|
$
|
1,229
|
|
|
$
|
5,486
|
|
|
(a)
|
The Corporate entity consists primarily of the general and
administrative activities of the Company.
|
|
(b)
|
A portion of the 2015 amounts were reclassified from DDS to
DPM to better align business activities within segments. This reclassification impacted
contract revenue and income (loss) from operations for 2015.
|
The following table summarizes other information by segment
as of and for the three-month period ended March 31, 2016:
|
|
DDS
|
|
|
API
|
|
|
DPM
|
|
|
Total
|
|
Long-lived assets
|
|
$
|
136,787
|
|
|
$
|
211,804
|
|
|
$
|
161,919
|
|
|
$
|
510,510
|
|
Total assets
|
|
|
206,141
|
|
|
|
448,034
|
|
|
|
180,038
|
|
|
|
834,213
|
|
Goodwill included in total assets
|
|
|
46,049
|
|
|
|
48,949
|
|
|
|
77,884
|
|
|
|
172,882
|
|
Investments in unconsolidated affiliates
|
|
|
956
|
|
|
|
—
|
|
|
|
—
|
|
|
|
956
|
|
Capital expenditures
|
|
|
4,194
|
|
|
|
6,578
|
|
|
|
857
|
|
|
|
11,629
|
|
The following table summarizes other information by segment
as of and for the three-month period ended March 31, 2015:
|
|
DDS
|
|
|
API
|
|
|
DPM
|
|
|
Total
|
|
Long-lived assets
|
|
$
|
78,159
|
|
|
$
|
103,058
|
|
|
$
|
128,605
|
|
|
$
|
309,822
|
|
Total assets
|
|
|
162,147
|
|
|
|
274,193
|
|
|
|
134,802
|
|
|
|
571,142
|
|
Goodwill included in total assets
|
|
|
17,830
|
|
|
|
16,899
|
|
|
|
58,130
|
|
|
|
92,859
|
|
Investments in unconsolidated affiliates
|
|
|
956
|
|
|
|
—
|
|
|
|
—
|
|
|
|
956
|
|
Capital expenditures
|
|
|
1,493
|
|
|
|
2,211
|
|
|
|
423
|
|
|
|
4,127
|
|
Note 10 — Financial Information by Customer Concentration
and Geographic Area
Total percentages of contract revenues
by each segment’s three largest customers for the three months ended March 31, 2016 and 2015 are indicated in the following
table:
|
|
|
Three Months Ended
March 31,
|
|
|
|
2016
|
|
2015
|
|
|
|
|
|
|
DDS
|
|
|
11%, 4%, 3%
|
|
11%, 10%, 4%
|
API
|
|
|
18%, 10%, 8%
|
|
25%, 16%, 11%
|
DPM
|
|
|
13%, 13%, 6%
|
|
12%, 12%, 11%
|
Total contract revenue from GE Healthcare
(“GE”), the Company’s largest customer, represented 9% and 13% of total contract revenue for the three
months ended March 31, 2016 and 2015, respectively.
The Company’s total contract revenue
for the three months ended March 31, 2016 and 2015 was recognized from customers in the following geographic regions:
|
|
Three Months Ended March 31,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
|
|
|
|
|
United States
|
|
|
62
|
%
|
|
|
69
|
%
|
Europe
|
|
|
29
|
|
|
|
25
|
|
Asia
|
|
|
5
|
|
|
|
4
|
|
Other
|
|
|
4
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
100
|
%
|
|
|
100
|
%
|
Long-lived assets, including goodwill,
by geographic region are as follows:
|
|
March 31,
2016
|
|
|
December 31,
2015
|
|
United States
|
|
$
|
331,553
|
|
|
$
|
323,667
|
|
Asia
|
|
|
13,678
|
|
|
|
14,336
|
|
Europe
|
|
|
165,279
|
|
|
|
161,696
|
|
Total long-lived assets
|
|
$
|
510,510
|
|
|
$
|
499,699
|
|
Note 11 — Legal Proceedings and Other
The Company, from time to time, may be
involved in various claims and legal proceedings arising in the ordinary course of business. Except as noted below, the Company
is not currently a party to any such claims or proceedings which, if decided adversely to the Company, would either individually
or in the aggregate have a material adverse effect on the Company’s business, financial condition, results of operations
or cash flows.
On November 12, 2014, a purported class
action lawsuit,
John Gauquie v. Albany Molecular Research, Inc., et al.
, No. 14-cv-6637, was filed against the Company
and certain of its current and former officers in the United States District Court for the Eastern District of New York. The
complaint alleges claims under the Securities Exchange Act of 1934 arising from the Company’s August 5, 2014 announcement
of its financial results for the second quarter of 2014, including that the OsoBio New Mexico facility experienced a power interruption
in July 2014, which would have a material impact on the Company’s results. The complaint alleges that the price of
the Company’s stock was artificially inflated between August 5, 2014 and November 5, 2014, and seeks certification as a
class action, unspecified monetary damages and attorneys’ fees and costs. The complaint was amended on March 31, 2015 to
request certification of a class of investors during the period between August 5, 2014 and November 5, 2014. On October 2, 2015,
the Company submitted a motion to dismiss the complaint, as amended.
Note 12 – Fair Value of Financial Instruments
The Company uses a framework for measuring
fair value in generally accepted accounting principles and making disclosures about fair value measurements. A three-tiered
fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value.
These tiers include:
Level 1 – defined as quoted prices
in active markets for identical instruments;
Level 2 – defined as inputs other
than quoted prices in active markets that are either directly or indirectly observable; and
Level 3 – defined as unobservable
inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
The Company determines the fair value
of its financial instruments using the following methods and assumptions:
Cash and cash equivalents, restricted
cash, receivables, and accounts payable:
The carrying amounts reported in the consolidated balance sheets approximate
their fair value because of the short maturities of these instruments.
Convertible senior notes, derivatives
and hedging instruments:
The fair values of the Company’s Notes, which differ from their carrying values, are influenced
by interest rates and the Company’s stock price and stock price volatility and are determined by prices for the Notes observed
in market trading, which are level 2 inputs. The estimated fair value of the Notes at March 31, 2016 was $164,657. The Notes Hedges
and the Notes Conversion Derivative are measured at fair value using level 2 inputs. These instruments are not actively traded
and are valued using an option pricing model that uses observable market data for all inputs, such as implied volatility of the
Company’s common stock, risk-free interest rate and other factors.
Interest rate swaps:
At March
31, 2016, the Company had contracted a derivative financial instrument to reduce the impact of fluctuations in variable
interest rates on a loan that a financial institution granted in February 2015, which is a level 2 input. The estimated fair
value of the swap at March 31, 2016 was $69. The Company hedges the interest risk of the initial amount of the aforementioned
bank loan through an interest rate swap. In this arrangement, the interest rates are exchanged so that the Company receives
from the financial institution a variable rate of the 3-month Euribor, in exchange for a fixed interest payment for the same
nominal (0.3%). The variable interest rate received for the derivative offsets the interest payment on the hedged
transaction, with the end result being a fixed interest payment on the hedged financing. At March 31, 2016, the derivative
financial instrument had not been designated as a hedge.
To determine the fair value of the interest
rate swap, the Company uses cash flow discounting based on the implicit rates determined by the euro interest rate curve, according
to market conditions at the valuation date.
Instrument
|
|
Nominal Amount
at 3/31/2016
|
|
|
Contract
Date
|
|
Contract
Date
Expiration
|
|
Interest
Rate
Payable
|
|
Interest Rate
Receivable
|
Interest rate swap
|
|
$
|
6,268
|
|
|
2/19/2015
|
|
2/19/2020
|
|
3-month Euribor
|
|
Fixed rate of 0.30%
|
Long-term debt, other than convertible
senior notes:
The carrying value of long-term debt approximated fair value at March 31, 2016 due to the resetting dates
of the variable interest rates.
Note 13 – Accumulated Other Comprehensive Loss, Net
The activity related to accumulated other comprehensive loss,
net was as follows:
|
|
Pension and
postretirement
benefit plans
|
|
|
Foreign
currency
adjustments
|
|
|
Total
Accumulated
Other
Comprehensive
Loss
|
|
Balance at December 31, 2015, net of tax
|
|
$
|
(5,581
|
)
|
|
$
|
(12,820
|
)
|
|
$
|
(18,401
|
)
|
Net current period change, net of tax
|
|
|
115
|
|
|
|
5,794
|
|
|
|
5,909
|
|
Balance at March 31, 2016, net of tax
|
|
$
|
(5,466
|
)
|
|
|
(7,026
|
)
|
|
|
(12,492
|
)
|
The following table provides additional details of the amounts
recognized into net earnings from accumulated other comprehensive loss, net:
|
|
Three Months Ended
|
|
|
|
March 31,
2016
|
|
|
March 31,
2015
|
|
Actuarial losses before tax effect (a)
|
|
$
|
177
|
|
|
$
|
237
|
|
Tax benefit on amounts reclassified into earnings
|
|
|
(62
|
)
|
|
|
(83
|
)
|
|
|
$
|
115
|
|
|
$
|
154
|
|
|
(a)
|
Amounts represent amortization of net actuarial loss
from shareholders’ equity into postretirement benefit plan cost. This amount was primarily recognized as cost of contract
revenue in the consolidated statement of operations.
|
Note 14 – Subsequent Event
On May 5, 2016, the Company entered into
a Share Purchase Agreement with Lauro Cinquantasette S.p.A., pursuant to which the Company intends to acquire all of the capital
stock of Prime European Therapeuticals S.p.A. (“Euticals”) (the “Euticals Acquisition”). The Share Purchase
Agreement provides for an aggregate purchase price of approximately €315,000, which consists of approximately (i) €164,000
paid in cash at the closing of the transaction, (ii) the issuance of approximately 7,000 unregistered shares of the Company’s
common stock, and (iii) €55,000 in seller notes issued by the Company. The Company expects to enter into a forward contract
in order to mitigate its exposure to currency fluctuations associated with the Euro-denominated purchase price. The Company
expects to close the Euticals Acquisition in the third quarter of 2016, subject to customary closing conditions, including Hart-Scott-Rodino
clearance in the U.S.
In connection with the Euticals Acquisition,
JPMorgan Chase Bank, N.A. and Barclays Bank PLC (the “Lead Arrangers”) have entered into a commitment letter (the “Commitment
Letter”) with the Company to provide financing to the Company for a portion of the purchase price. Pursuant to the commitment
letter, the Lead Arrangers have committed to provide either (x) incremental senior secured first lien term loans in an aggregate
principal amount of up to $230,000 and incremental revolving loans in an aggregate amount of up to $5,000 pursuant to an amendment
to the Second Restated Credit Agreement (the “Amendment”), provided that the requisite consents to approve the Amendment
are obtained from the Company’s existing lenders or (y) if such requisite consents are not obtained, senior secured first
lien credit facilities consisting of up to $428,300 of first lien term loans and up to $35,000 of first lien revolving loans; in
each case subject to the conditions set forth in the Commitment Letter.
Upon closing of the Euticals Acquisition,
the acquisition financing, anticipated to be in the U.S., would result in additional interest expense in the U.S. We currently
have U.S. net deferred tax assets of $8,100, including net operating loss carryforwards. The increase in U.S. expenses could
limit the Company’s ability to utilize currently available tax attributes resulting in the potential for additional valuation
allowance recognized upon the effective closing of the transaction.